Get the Stockscreener App
0.823
1.14%
0.0093
Pasithea Therapeutics Corp stock is traded at $0.823, with a volume of 89,409.
It is up +1.14% in the last 24 hours and up +4.10% over the past month.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
See More
Previous Close:
$0.8137
Open:
$0.8113
24h Volume:
89,409
Relative Volume:
0.80
Market Cap:
$6.13M
Revenue:
-
Net Income/Loss:
$-16.28M
P/E Ratio:
-0.0592
EPS:
-13.91
Net Cash Flow:
$-13.75M
1W Performance:
+16.19%
1M Performance:
+4.10%
6M Performance:
-41.21%
1Y Performance:
-78.34%
1-Day Range:
$0.8003
$0.8392
1-Week Range:
$0.691
$0.84
52-Week Range:
$0.65
$4.35
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Name
Pasithea Therapeutics Corp
Sector
Industry
Phone
(702) 514-4174
Address
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.823 | 6.06M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.62 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.93 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.49 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
823.27 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.13 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Pasithea Therapeutics Corp Stock (KTTA) Latest News
Backtesting results for Pasithea Therapeutics Corp. Equity Warrant trading strategies2025 Bull vs Bear & Smart Money Movement Alerts - newser.com
Does Pasithea Therapeutics Corp. Equity Warrant qualify in momentum factor screening2025 Analyst Calls & Growth Oriented Trading Recommendations - newser.com
Pasithea Therapeutics Corp. stock trend forecastStock Surge & AI Driven Price Predictions - newser.com
Will breakout in Pasithea Therapeutics Corp. lead to full recovery2025 Support & Resistance & Daily Profit Maximizing Trade Tips - newser.com
Pasithea Therapeutics Corp.’s volatility index tracking explainedJuly 2025 Market Mood & AI Powered Market Entry Strategies - newser.com
Automated trading signals detected on Pasithea Therapeutics Corp. Equity Warrant2025 EndofYear Setup & Trade Opportunity Analysis - newser.com
Is it too late to sell Pasithea Therapeutics Corp.July 2025 Update & Fast Entry High Yield Tips - newser.com
Is Pasithea Therapeutics Corp. Equity Warrant stock positioned for long term growthWeekly Risk Report & Fast Exit Strategy with Risk Control - newser.com
Can Pasithea Therapeutics Corp. Equity Warrant stock beat market expectations this quarterQuarterly Portfolio Summary & Community Consensus Trade Alerts - newser.com
Real time social sentiment graph for Pasithea Therapeutics Corp. Equity WarrantJuly 2025 Breakouts & Verified Chart Pattern Signals - newser.com
Has Pasithea Therapeutics Corp. formed a bullish divergenceQuarterly Profit Summary & Verified Entry Point Signals - newser.com
Is Pasithea Therapeutics Corp. stock cheap compared to fundamentalsEarnings Recap Summary & Daily Stock Momentum Reports - newser.com
Pasithea Therapeutics Corp. Equity Warrant stock daily chart insightsJuly 2025 Breakouts & Safe Swing Trade Setups - newser.com
Is Pasithea Therapeutics Corp. stock a dividend growth opportunityJuly 2025 Sector Moves & Growth Focused Stock Reports - newser.com
Is Pasithea Therapeutics Corp. stock a safe investment in uncertain marketsTreasury Yields & Weekly Market Pulse Updates - newser.com
Will Pasithea Therapeutics Corp. Equity Warrant stock outperform value stocksJuly 2025 Opening Moves & Intraday High Probability Alerts - newser.com
Is Pasithea Therapeutics Corp. stock a buy for dividend growthEarnings Risk Report & Low Risk Profit Maximizing Plans - newser.com
Has Pasithea Therapeutics Corp. Equity Warrant found a price floorJuly 2025 Action & Community Consensus Picks - newser.com
Will Pasithea Therapeutics Corp. stock outperform tech sector in 2025Portfolio Risk Report & Weekly High Conviction Trade Ideas - newser.com
What institutional flow reveals about Pasithea Therapeutics Corp. Equity WarrantPortfolio Return Summary & Expert Approved Momentum Trade Ideas - newser.com
Can Pasithea Therapeutics Corp. stock outperform in 2025 bull marketDip Buying & Advanced Swing Trade Entry Alerts - newser.com
Will Pasithea Therapeutics Corp. Equity Warrant stock continue dividend increasesMarket Sentiment Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Chart based analysis of Pasithea Therapeutics Corp. Equity Warrant trendsLayoff News & Smart Swing Trading Techniques - newser.com
Short interest data insights for Pasithea Therapeutics Corp.Quarterly Profit Report & Safe Capital Preservation Plans - newser.com
Applying sector rotation models to Pasithea Therapeutics Corp. Equity WarrantJuly 2025 Patterns & Safe Entry Momentum Tips - newser.com
Can Pasithea Therapeutics Corp. stock attract ESG capital inflowsEntry Point & Community Verified Trade Signals - newser.com
Is Pasithea Therapeutics Corp. reversing from oversold territory2025 Winners & Losers & Low Risk Entry Point Guides - newser.com
Pasithea Therapeutics Corp. stock chart pattern explained2025 Dividend Review & Community Shared Stock Ideas - newser.com
Pasithea Therapeutics Corp Equity Warrant Stock Analysis and ForecastPrice Support Zones & Get Mentorship from Elite Traders - earlytimes.in
Pasithea Therapeutics Corp Stock (KTTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pasithea Therapeutics Corp Stock (KTTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
May 12 '25 |
Sale |
0.82 |
960 |
792 |
40,001 |
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):